Skip to Content

Adocia ADR ADOCY

Morningstar Rating
$11.80 +2.00 (20.41%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADOCY is trading at a 41% discount.
Price
$11.74
Fair Value
$93.63
Uncertainty
Extreme
1-Star Price
$334.33
5-Star Price
$1.76
Economic Moat
Cffd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADOCY is a good fit for your portfolio.

Trading Information

Previous Close Price
$9.80
Day Range
$11.8011.80
52-Week Range
$11.8011.80
Bid/Ask
$0.00 / $14.22
Market Cap
$95.48 Mil
Volume/Avg
760 / 760

Key Statistics

Price/Earnings (Normalized)
Price/Sales
111.56
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
107

Valuation

Metric
ADOCY
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
111.56
Price/Cash Flow
Price/Earnings
ADOCY

Financial Strength

Metric
ADOCY
Quick Ratio
0.57
Current Ratio
0.60
Interest Coverage
−6.09
Quick Ratio
ADOCY

Profitability

Metric
ADOCY
Return on Assets (Normalized)
−58.15%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−79.63%
Return on Assets
ADOCY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYlnbvfwctXkjgl$570.1 Bil
VRTX
Vertex Pharmaceuticals IncZggmqhhXmnwtb$108.0 Bil
REGN
Regeneron Pharmaceuticals IncSwwlpphfcBbstq$105.6 Bil
MRNA
Moderna IncPgpmlvpxNxmv$40.8 Bil
BNTX
BioNTech SE ADRNjyzngcqSydrb$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncGmpvdhyQzkhvm$18.8 Bil
BMRN
Biomarin Pharmaceutical IncXqtmbgwzhMftdyk$16.5 Bil
RPRX
Royalty Pharma PLC Class AYlwqllnwWygjgd$13.6 Bil
INCY
Incyte CorpSpvgqxxfXblfnp$12.8 Bil
UTHR
United Therapeutics CorpRbzvktmsWcjg$10.8 Bil

Sponsor Center